Cardio Diagnostics Holdings, Inc. (CDIOW) Aandelenanalyse

Bedrijfsoverzicht

Cardio Diagnostics Holdings, Inc. is a specialized entity focused on the development and commercialization of epigenetics-based clinical tests designed specifically for the assessment of cardiovascular disease. The organization operates within a niche segment of the healthcare industry, utilizing epigenetic markers to provide risk assessments for conditions such as coronary heart disease and heart attacks through its proprietary Epi+Gen CHD and Precisio testing platforms. In terms of operational scale, the company currently employs a workforce of 15 individuals to support its research and commercialization efforts. The available data indicates that the market capitalization is listed as not applicable, while the reported annual revenue for the trailing twelve months stands at $14,825, reflecting the early-stage or micro-cap nature of the enterprise. These financial figures, combined with the minimal headcount, suggest that the company is in a developmental phase where capital allocation is heavily weighted toward research and development rather than established commercial profitability, positioning it as a high-risk, high-potential venture within the broader biomedical sector.

Financiële gezondheid

The financial performance of Cardio Diagnostics Holdings, Inc. over the trailing twelve months demonstrates a significant structural challenge, with revenue of $14,825 contrasted sharply against a net income loss of $-6,498,167. This substantial divergence between minimal revenue and massive net losses reveals a cost structure dominated by heavy research and development expenditures or operational inefficiencies that far outweigh current sales generation. The company's EBITDA for the same period was $-6,085,950, indicating that even before interest and tax considerations, the core business operations are generating significant negative cash conversion. Free cash flow for the trailing twelve months was recorded at $-3,809,743, which signifies a complete lack of financial flexibility to fund operations or investments through internal cash generation without external financing. The gross margin stands at an unusual 100.0%, while the operating margin is listed as -41159.6% and the profit margin as 0.0%, suggesting a severe distortion in operating expenses relative to the tiny revenue base. Regarding liquidity, the company holds $5.11M in cash against total debt of $695,619, yet the debt-to-equity ratio is reported as 9.97, highlighting a highly leveraged position relative to shareholders' equity. The current ratio of 9.79 indicates that the company possesses ample short-term assets to cover its short-term liabilities, providing a buffer against immediate liquidity crises despite the overall loss-making status. Furthermore, the return on equity is -78.6% and the return on assets is -44.1%, metrics that explicitly reveal that management is currently destroying value rather than generating returns for shareholders or efficiently utilizing the asset base.

Waarderingsbeoordeling

Trailing twelve-month and forward P/E ratios are both listed as not applicable due to the company's negative earnings, which implies that traditional valuation multiples based on profitability cannot be calculated at this stage. The price-to-book ratio is recorded as 0.00, indicating that the market valuation of the equity is effectively zero relative to the company's accounting book value. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also not applicable, suggesting that investors must rely on asset-backed or revenue-based metrics rather than earnings multiples for valuation analysis. The stock has exhibited a range of $0.02 for both the 52-week high and the 52-week low, meaning the current trading price is effectively at the lower bound of its annual trading range with no price appreciation or depreciation observed within this period. With a beta of 2.66, the stock demonstrates extreme price volatility, moving with a magnitude more than double that of the broader market, which reflects the heightened risk associated with small-cap biotechnology firms. This high beta value signifies that price fluctuations are likely to be amplified during periods of market stress or sector-specific news, making the asset sensitive to macroeconomic shifts.

Growth & Income

Year-over-year revenue growth is reported at -21.2%, while earnings growth is listed as not applicable due to the absence of prior period positive earnings for comparison. The decline in revenue indicates a contraction in business activity or a failure to scale commercial efforts, and since earnings are already negative, there is no earnings growth trajectory to analyze against revenue changes. As a non-dividend payer, the company does not distribute a dividend yield or a payout ratio, meaning all available cash is theoretically retained for reinvestment into its epigenetic testing technologies rather than being returned to shareholders. This reinvestment strategy is typical for pre-revenue or loss-making biotech firms attempting to bridge the gap to profitability. The overall growth and income profile is characterized by negative revenue momentum and a complete absence of income distribution, presenting a scenario where capital preservation is the primary concern rather than capital appreciation through dividends or earnings expansion.